comparemela.com

Latest Breaking News On - Adunolimab - Page 1 : comparemela.com

Cantargia publishes ASCO 2023 poster on promising nadunolimab efficacy in non-small cell lung cancer

Cantargia today presented interim efficacy data for 39 non-small cell lung cancer patients treated with nadunolimab and platinum-based chemotherapy as a poster at the ASCO Annual Meeting 2023 , and. | June 4, 2023

Luis pazNon small cellCantargia ab publ stock exchangePress release023 canta se0006371126

Cantargia AB: Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023

LUND, Sweden, April 4, 2023 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day focusing on new clinical results and biomarker data for

Region flamandeDavid libergVan cutsemDominique tersagoEric van cutsemPrnewswire cantargiaUniversity hospitals gasthuisbergVp researchUniversity of warsawBelgian foundationNasdaq stockholmDivision headDigestive oncologyEric vanMedical universityProf van cutsem

Cantargia AB: Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer

LUND, Sweden, March 14, 2023 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported that two abstracts on its lead asset, the antibody nadunolimab (CAN04), have been

Dennis riedlPrnewswire cantargiaClinical research excluding trialsNasdaq stockholmClinical research excludingTherapeutic benefitMonday aprWednesday apr

Cantargia AB: Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer

LUND, Sweden, Feb. 23, 2023 /PRNewswire/ Cantargia (Cantargia AB) (NASDAQ Stockholm: CANTA) today reported favorable safety and promising early signs of efficacy following an initial analysis

Dennis riedlDurani reynalsAgostina stradellaPrnewswire cantargiaCatalan institute of oncologySpanish breast cancer groupPrincipal investigatorCatalan instituteNasdaq stockholm

Cantargia - New data support differentiation of nadunolimab

Cantargia has presented new data concerning its IL1RAP-targeting antibody, nadunolimab (CAN04), which demonstrates the drug's ability to reduce levels of tumour-promoting molecules in a pancreatic cancer

Kostenloser wertpapierhandel

vimarsana © 2020. All Rights Reserved.